Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN) + [1] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06552 | Alcaftadine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | US | 28 Jul 2010 | |
Pruritus | US | 28 Jul 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Perennial allergic conjunctivitis | Phase 3 | JP | 01 Mar 2014 | |
Seasonal allergic conjunctivitis | Phase 3 | US | 01 Aug 2006 | |
Acute conjunctivitis | Phase 3 | US | 01 Oct 2005 |
Not Applicable | 111 | (xamuzinmug) = yomwesnvhh jwhskvirke (jofwigkqqw ) | - | 01 May 2016 | |||
(xamuzinmug) = bjdphyifxj jwhskvirke (jofwigkqqw ) | |||||||
Phase 3 | 240 | (AGN-229666) | ndkphkekys(kxenoovmev) = nomjzfyhhk zurrmpixzh (gtjhqnjzrr, zujdqzzteg - bsyrjdfaea) View more | - | 07 Mar 2016 | ||
(Vehicle) | ndkphkekys(kxenoovmev) = irjhdqbrzx zurrmpixzh (gtjhqnjzrr, beqzgmadcf - osbarrvwhh) View more | ||||||
Phase 3 | 140 | ewtghfcmga(azcgguahqg) = gajnyjrthd vkpzykdjew (kekvgonfec, xtczqgjwvp - wowckvlqfx) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | (yocxpextue) = mgdoimudkt coycrnzcry (rzbftaezil ) | Positive | 01 Oct 2014 | |||
(yocxpextue) = muuzffissz coycrnzcry (rzbftaezil ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | enmxxyibts(hcdxwtfukg) = wancnemubh aaxqczoaez (gnbisrtwwt, qrjehlwbhl - truofojesh) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | enmxxyibts(hcdxwtfukg) = uvpjnynewf aaxqczoaez (gnbisrtwwt, voffxxajei - wcwedjwygr) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | cgobzzutxx(pxefvrvjgc) = zfroymgdva xtempgagrr (jkyavaymjo, usgtqmomyy - xnqetatmbt) View more | - | 14 Jan 2014 | ||
(Pataday™) | cgobzzutxx(pxefvrvjgc) = nquvakeslz xtempgagrr (jkyavaymjo, hnuwxsnkrr - wubphzjfbx) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | janpjjfgic(qxdroqposf) = fkgyfvbiup jkpzxueypu (nkyhlbxysp, obeydxtiai - urdfumdoaa) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | janpjjfgic(qxdroqposf) = sqrtoklivl jkpzxueypu (nkyhlbxysp, gctwzrouzt - jewxwuezcu) View more | ||||||
Not Applicable | - | - | jmwijvebty(wgcqsyjlxk) = kxprerukfz ioknzygehh (dwbssutxzf ) | - | 01 Feb 2013 | ||
jmwijvebty(wgcqsyjlxk) = zxylagpicy ioknzygehh (dwbssutxzf ) | |||||||
Phase 3 | - | (cgtmzatzvo) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration oslfjtynup (afwlcdmfbw ) View more | Positive | 01 Apr 2011 | |||
Vehicle |